Bio-Techne Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 69.40.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bio-Techne Corp's Score
Industry at a Glance
Industry Ranking
49 / 404
Overall Ranking
144 / 4592
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
17
analysts
Buy
Current Rating
69.402
Target Price
+15.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bio-Techne Corp Highlights
StrengthsRisks
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.
Overvalued
The company’s latest PE is 117.16, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 161.18M shares, decreasing 4.35% quarter-over-quarter.
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Ticker SymbolTECH
CompanyBio-Techne Corp
CEOKelderman (Kim)
Websitehttps://www.bio-techne.com/
FAQs
What is the current price of Bio-Techne Corp (TECH)?
The current price of Bio-Techne Corp (TECH) is 58.510.
What is the symbol of Bio-Techne Corp?
The ticker symbol of Bio-Techne Corp is TECH.
What is the 52-week high of Bio-Techne Corp?
The 52-week high of Bio-Techne Corp is 79.280.
What is the 52-week low of Bio-Techne Corp?
The 52-week low of Bio-Techne Corp is 46.010.
What is the market capitalization of Bio-Techne Corp?
The market capitalization of Bio-Techne Corp is 9.11B.
What is the net income of Bio-Techne Corp?
The net income of Bio-Techne Corp is 73.36M.
Is Bio-Techne Corp (TECH) currently rated as Buy, Hold, or Sell?
According to analysts, Bio-Techne Corp (TECH) has an overall rating of Buy, with a price target of 69.402.
What is the Earnings Per Share (EPS TTM) of Bio-Techne Corp (TECH)?
The Earnings Per Share (EPS TTM) of Bio-Techne Corp (TECH) is 0.499.